Pfizer – Ulcerative Colitis (UC) Research – RFP

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Geographic Scope: Select European countries (please see RFP for specifics), Canada, South Korea, Australia, New Zealand, Israel

Clinical Area: Ulcerative Colitis (UC)

Link to full RFP: Ulcerative Colitis (UC) Research

Application Due Date: September 12, 2023

Specific Area of Interest: Pfizer is interested in supporting research proposals that advance our understanding of ulcerative colitis through research focused in the following areas:

• For patients treated with S1P receptor modulators, exploration for optimal markers (including clinical, endoscopic, histologic, ultrasonographic, genetics, and other measured markers) to assess and potentially predict response to treatment
• Correlation of effects of S1P receptor modulator and Microbiome
• Elucidate the role of S1P receptor modulators in the treatment of extra-intestinal manifestations (EIM) of UC
• Assess mechanistic association of S1P receptor modulation with reduced inflammation in colonic tissue beyond lymphocyte egress